GenSci142

Phase 1Small molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

GenSci142 is one of 7 small molecule programs targeting Single Ascending Dose. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Single Ascending DoseNot yet recruiting

Single Ascending DosePhase 1

Not yet recruiting

Competition

Competitive Landscape

12 competitors in Single Ascending Dose

#DrugCompanyPhaseTrials

SYH2085

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1

1 2

JMT202

SShanghai JMT-Bio Inc.

Phase 1

1 3

DT-216P2

DDesign Therapeutics, Inc.

Phase 1

1 4

GenSci142

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

1 5

HRS-4029

BBeijing Suncadia Pharmaceuticals Co., Ltd

Phase 1

1 6

NM-101

NNeuramedy Co. Ltd.

Phase 1

1 7

WVE-006

WWave Life Sciences Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Single Ascending Dose

NCT07302035

Q2 2027

Phase 1Recruiting

Bacterial Vaginosis

NCT07663838

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07302035·30 enrolled

Bacterial Vaginosis1 trial

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07663838·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GenSci142. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GenSci142 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GenSci142. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

GenSci142

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Single Ascending Dose1 trial

Bacterial Vaginosis1 trial

References

Drug Info

Quick Facts

Related News